Tag Archives: Mayank Mamtani

Cassava Sciences (SAVA) Has a New Rating from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani initiated coverage with a Buy rating on Cassava Sciences (SAVA – Research Report) yesterday and set a price target of $78.00. The company’s shares closed last Monday at $41.81. According to TipRanks.com, Mamtani is a

B.Riley Financial Initiates a Buy Rating on Inmune Bio (INMB)

Inmune Bio (INMB – Research Report) received a Buy rating and a $29.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares closed last Tuesday at $11.02. According to TipRanks.com, Mamtani is a 5-star analyst with an

B.Riley Financial Reiterates a Buy Rating on Spectrum Pharmaceuticals (SPPI)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $3.07. According to TipRanks.com, Mamtani is

TFF Pharmaceuticals (TFFP) Receives a Buy from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report) today and set a price target of $36.00. The company’s shares closed last Friday at $15.55. According to TipRanks.com, Mamtani is a 5-star analyst

B.Riley Financial Sticks to Their Buy Rating for Agenus (AGEN)

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Agenus (AGEN – Research Report) on January 8 and set a price target of $8.00. The company’s shares closed last Thursday at $3.42. According to TipRanks.com, Mamtani is a 5-star

B.Riley Financial Believes TFF Pharmaceuticals (NASDAQ: TFFP) Won’t Stop Here

In a report issued on January 8, Mayank Mamtani from B.Riley Financial maintained a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), with a price target of $36.00. The company’s shares closed last Thursday at $18.25, close to its